Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial.

@article{Nijhawan1999LevosimendanEC,
  title={Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial.},
  author={N Nijhawan and Alfred C. Nicolosi and Matthew Montgomery and Avichal Aggarwal and P S Pagel and David C. Warltier},
  journal={Journal of cardiovascular pharmacology},
  year={1999},
  volume={34 2},
  pages={219-28}
}
Levosimendan is a new myofilament calcium (Ca2+) sensitizer that increases myocardial contractility by stabilizing the Ca2+-bound conformation of troponin C. We tested the hypothesis that levosimendan enhances cardiac performance after cardiopulmonary bypass (CPB). Anesthesia was induced and maintained with midazolam, sufentanil, and vecuronium in 18 patients randomly assigned to receive levosimendan (18 or 36 microg/kg loading dose and 0.2 or 0.3 microg/kg/min infusion, respectively) or… CONTINUE READING
58 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

Similar Papers

Loading similar papers…